EyePoint Pharmaceuticals
Tracked across 1 events · 22 articles · First seen Aug 21, 2026 · Last active Sep 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
On August 17, 2026, EyePoint Pharmaceuticals announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration. The trial failed to meet its prespecified…
Impact: EyePoint is the central company whose lead drug candidate DURAVYU failed its Phase 3 trial, causing a massive stock decline and triggering securities investigations.
Aug 21, 2026 · 22 articles
100
EyePoint Pharmaceuticals disclosed missed endpointEyePoint DURAVYU Phase 3...
80
Levi & Korsinsky commenced investigation EyePoint PharmaceuticalsEyePoint DURAVYU Phase 3...
80
Kessler Topaz Meltzer & Check launched investigation EyePoint PharmaceuticalsEyePoint DURAVYU Phase 3...
80
Pomerantz LLP launched investigation EyePoint PharmaceuticalsEyePoint DURAVYU Phase 3...
ERGEN INTELLIGENCE
Track EyePoint Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard